

Analysis of integration site distributions and clonal abundances for lentiviral vector-based correction of cystinosis

John K. Everett, Ph.D. and Frederic Bushman, Ph.D.

December 2021

Contents

Table 1. Overview of data collection.

Sample ID	Sample Name	Cell Type	Reads	Inferred Cells	Unique Sites	S. Chao1	Shannon	Gini	Simpson	UC50
GTSP4888	IPSC_1	IPSC	180529	42815	12874	18485	8.957	0.506	1.000	1909
GTSP4889	IPSC_2	IPSC	175908	39196	6247	7636	8.169	0.561	1.000	865
GTSP4890	IPSC_3	IPSC	161136	39553	4631	5792	7.627	0.645	0.999	424
GTSP4891	IPSC_4	IPSC	176013	35207	3116	4097	7.150	0.679	0.999	283
GTSP4892	Myopaxon_5	MYOPAXON	163706	32650	4544	7187	7.169	0.725	0.998	215
GTSP4893	Myopaxon_6	MYOPAXON	173432	26218	3237	5458	6.639	0.761	0.997	113
GTSP4894	Myopaxon_7	MYOPAXON	178276	27920	1894	2542	6.432	0.740	0.997	128
GTSP4895	Myopaxon_8	MYOPAXON	167465	19260	1422	2138	6.088	0.751	0.996	87
GTSP4896	Myopaxon_9	MYOPAXON	199223	26413	1076	1500	5.838	0.756	0.995	74
GTSP4897	Myopaxon_10	MYOPAXON	182630	30814	1045	1336	5.847	0.745	0.995	76

```
## Rows: 10 Columns: 3
## -- Column specification -----
## Delimiter: "\t"
## chr (3): SampleID, SampleName, SamplePatientCode
##
## i Use `spec()` to retrieve the full column specification for this data.
## i Specify the column types or set `show_col_types = FALSE` to quiet this message.
```

Table 1. Overview of data collection.

Fisher's exact test	A near oncogenes	B near oncogenes	p-value
iPSC vs Myopaxon	18.91%	18.44%	3.10e-01
iPSC vs published trials	18.91%	24.24%	4.46e-87
Myopaxon vs published trials	18.44%	24.24%	8.84e-43
(iPSC + Myopaxon) vs published trials	18.80%	24.24%	4.10e-100
(iPSC + Myopaxon) vs WAS	18.80%	23.40%	7.06e-45
(iPSC + Myopaxon) vs CGD	18.80%	22.56%	4.33e-46
(iPSC + Myopaxon) vs betaThalassemia	18.80%	25.70%	3.37e-51
(iPSC + Myopaxon) vs CART19 ALL	18.80%	28.39%	3.39e-211

Table 2. Contributions towards clonal abundance from shared sites.

iPSC	iPSC relAbund from shared sites	Myopaxon	Myopaxon relAbund from shared sites
IPSC_1	31.04%	Myopaxon_5	86.67%
IPSC_1	25.70%	Myopaxon_6	90.98%
IPSC_2	33.60%	Myopaxon_7	94.99%
IPSC_3	41.36%	Myopaxon_8	96.88%
IPSC_4	44.42%	Myopaxon_9	98.80%
IPSC_4	41.70%	Myopaxon_10	96.31%

Supplemental table 1.

SampleID	SampleName	SamplePatientCode
GTSP4888	IPSC_1	TC-1133 (research)
GTSP4889	IPSC_2	ND50039 (W266020904721)
GTSP4890	IPSC_3	ND50039 (W266020904721)
GTSP4891	IPSC_4	W26602190549400
GTSP4892	Myopaxon_5	TC-1133 (research) (W26602190545121)
GTSP4893	Myopaxon_6	TC-1133 (research) (W26602190542200)
GTSP4894	Myopaxon_7	ND50039 (W266020904721)
GTSP4895	Myopaxon_8	ND50039 (W266020904721)
GTSP4896	Myopaxon_9	W26602190549400
GTSP4897	Myopaxon_10	W26602190576221